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and/or	 substance	use	disorders.3	Yet,	 fatigue	and	psychological	 is‐




free	 treatment	 regimens	 that	 likely	 are	more	 suitable	 for	 patients	
with	 chronic	 HCV	 infection	 and	 comorbid	 psychiatric	 disorders.	
Both	clinical	trials	and	real‐world	evidence	have	demonstrated	that	
these	all‐oral,	IFN‐free	regimens	are	highly	efficacious	and	well	tol‐










Glecaprevir	 (GLE;	 NS3/4A	 protease	 inhibitor	 identified	 by	
AbbVie	and	Enanta)	and	pibrentasvir	(PIB;	NS5A	inhibitor)	are	potent	
pangenotypic	inhibitors	co‐formulated	as	G/P,	an	all‐oral,	once‐daily	













(HIV).19‐26	 Preliminary	 reports	 from	 real‐world	 cohorts	 have	 sup‐









infection	 and	 either	 without	 cirrhosis	 or	 with	 compensated	 cirrhosis	
who	received	G/P	in	ten	Phase	2	and	Phase	3	clinical	trials	that	assessed	
efficacy,	 safety,	 treatment	 adherence	 and	 PROs	 (SURVEYOR‐I	 and	
SURVEYOR‐II	and	MAGELLAN‐1,	and	ENDURANCE‐1,	ENDURANCE‐2,	
ENDURANCE‐3	 and	 ENDURANCE‐4,	 and	 EXPEDITION‐1,	





























G/P	discontinuation	occurring	at	 similarly	 low	rates	 in	both	patient	populations.	 In	
conclusion,	G/P	treatment	was	highly	efficacious,	well‐tolerated	and	demonstrated	
high	adherence	rates	in	patients	with	chronic	HCV	infection	and	psychiatric	disorders.
K E Y W O R D S
chronic	hepatitis	C,	drug	interactions,	mental	disorders,	sustained	virologic	response,	
treatment adherence and compliance




or	 sofosbuvir	 +	RBV	±	pegIFN.	Medical	 history	 of	 psychiatric	 dis‐







or	 disorders	 not	 related	 to	 existing	 HCV	 infection.	 Patients	 were	












In	 this	 post	 hoc	 analysis,	 patients	 receiving	 at	 least	 one	 dose	
of	G/P	were	 classified	as	having	a	psychiatric	disorder	by	medical	
history	 and/or	 concomitant	 medication	 use.	 Medical	 history	 was	
used	to	classify	patients	as	having	a	psychiatric	disorder	if	they	had	
been	 previously	 diagnosed	 with	 any	 of	 the	 following	 psychiatric	
or	 neurological	 disorders	 including	 anxiety,	 bipolar	 disorder,	 cog‐
nitive	 or	 psychiatric	 disorder,	 depression,	 Parkinson's	 disease,	 and	





Real‐time	 reverse	 transcriptase‐polymerase	 chain	 reaction	 (RT‐
PCR)	was	 utilized	 to	 quantify	 plasma	HCV	RNA	 for	 both	 baseline	
viral	 load	 and	 SVR12	 assessments;	 assay	 details	 are	 described	 in	
the	Supporting	 Information.	HCV	genotype	was	determined	using	
the	 Versant®	 HCV	 Genotype	 Inno	 LiPA	 Assay,	 Version	 2.0	 or	
higher	 (LiPA;	Siemens	Healthcare	Diagnostics,	Tarrytown,	NY)	and	
confirmed	 by	 phylogenetic	 analysis	 of	 viral	 sequences.	 Treatment	









ment	 week	 12	 on	 the	 Short‐Form	 36	 (SF‐36)	Mental	 Component	
Summary	(MCS)	and	Fatigue	Severity	Scale	(FSS).
Safety	was	evaluated	by	monitoring	adverse	events	 (AEs),	vital	
signs,	 physical	 examination	 findings,	 electrocardiography	 and	 clin‐





All	 AEs	 were	 coded	 using	 the	 Medical	 Dictionary	 for	 Regulatory	










who	 reported	 treatment‐emergent	 adverse	 events	 and	 laboratory	
abnormalities,	both	in	total	and	stratified	by	the	presence	or	absence	
of	a	psychiatric	disorder.	Additional	endpoints	 included	analyses	of	












3.1 | Baseline patient demographics and 
characteristics
This	 analysis	 of	Phase	2	 and	Phase	3	 clinical	 trial	 data	 consisted	of	
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of	patients	with	or	without	a	psychiatric	disorder.	Patients	with	psy‐
chiatric	disorders	were	more	often	female	(49%	vs	40%,	respectively),	
white	 (87%	 vs	 77%,	 respectively),	 GT3‐infected	 (32%	 vs	 24%,	 re‐
spectively)	 and	had	higher	prevalence	of	 cirrhosis	 (16%	vs	11%,	 re‐
spectively)	 and	medical	 history	 of	 injection	 drug	 use	 (56%	 vs	 34%,	
respectively)	compared	to	those	without	a	psychiatric	disorder.
The	most	 common	concomitant	medication	 for	 each	of	 these	
neuropsychiatric	drug	classes	is	listed	in	Table	2	for	patients	with	or	
without	psychiatric	disorders	when	appropriate.	Among	the	most	
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3.3 | Efficacy outcomes




among	 patients	 with	 a	 psychiatric	 disorder	 compared	 to	 1.5%	
(26/1733)	 in	 patients	 without	 a	 psychiatric	 disorder.	 Nonvirologic	
TA B L E  2  Most	common	neuropsychiatric	co‐medications	by	anatomical	therapeutic	chemical	(ATC)	class
Drug class Medication
Patients with Psychiatric 
Disorders N = 789 (n, %)
Patients without a Psychiatric 
Disorder 
N = 1733 (n, %)
Overall 
N = 2522 (n, %)
Antidepressantsa Trazodone 62	(7.9) 0 62	(2.5)
Escitalopram 57	(7.3) 0 57	(2.3)
Citalopram 48	(6.1) 0 48	(1.9)
Bupropion 45	(5.7) 0 45	(1.8)
Sertraline 45	(5.7) 0 45	(1.8)
Opioids Codeineb 49	(6.2) 46	(2.7) 95	(3.8)
Tramadol 45	(5.7) 36	(2.1) 81	(3.2)
Oxycodoneb,c 52	(6.6) 29	(1.7) 81	(3.2)
Hydrocodoneb,c 50	(6.3) 27	(1.6) 77	(3.1)
Morphine 17	(2.2) 12	(0.7) 29	(1.1)
Anxiolytics Alprazolam 65	(8.2) 21	(1.2) 86	(3.4)
Clonazepam 44	(5.6) 8	(0.5) 52	(2.1)
Diazepam 42	(5.3) 10	(0.6) 52	(2.1)
Lorazepam 40	(5.1) 9	(0.5) 49	(1.9)
Hydroxyzine 15	(1.9) 14	(0.8) 29	(1.1)
Antiepileptic Gabapentin 68	(8.6) 31	(1.8) 99	(3.9)
Pregabalin 21	(2.7) 8	(0.5) 29	(1.1)
Lamotrigine 18	(2.3) 1	(<0.1) 19	(0.8)
Levetiracetam 15	(1.9) 2	(0.1) 17	(0.7)
Valproic	Acid 7	(0.9) 2	(0.1) 9	(0.4)
Hypnotics	and	sedatives Zolpidem 43	(5.4) 24	(1.4) 67	(2.4)
Diphenhydramine 27	(3.4) 17	(1) 44	(1.7)
Zopiclone 20	(2.5) 20	(1.2) 40	(1.6)
Melatonin 20	(2.5) 9	(0.5) 29	(1.1)
Promethazine 17	(2.2) 5	(0.3) 22	(0.9)
Antipsychoticsa Quetiapinec 47	(6) 0 47	(1.9)
Risperidone 18	(2.3) 0 18	(0.7)
Lithium 11	(1.4) 0 11	(0.4)
Olanzapine 11	(1.4) 0 11	(0.4)
Aripiprazole 9	(1.1) 0 9	(0.4)




Buprenorphine 18	(2.3) 8	(0.5) 26	(1.0)
Nicotine 10	(1.3) 14	(0.8) 24	(1.0)























with	 psychiatric	 disorders	 by	 common	 psychiatric	 diagnoses	 and	
neuropsychiatric	 co‐medication	 classes	 (Figure	 2).	 SVR12	 rates	






















serious	 AEs	 were	 rare	 (<1%)	 in	 both	 patients	 with	 and	 without	 a	
psychiatric	 disorder	 (Table	 4).	 Serious	AEs	occurred	 at	 similar	 fre‐
quencies	in	patients	with	and	without	psychiatric	disorders.	No	pa‐
tients	with	psychiatric	disorders	experienced	a	G/P‐related	serious	
AE	as	assessed	by	 the	 study	 investigator.	G/P‐related	AEs	 leading	
to	discontinuation	were	reported	in	5	(<1%)	patients,	including	two	
































































Patients with psychiatric 
disorder 
N = 789







































on Day 61. 
ePost‐nadir	increase	(in	grade).	
TA B L E  4  Adverse	events	and	
laboratory	abnormalities



































have	 shown	 similarly	 high	 adherence	 rates	 in	 clinical	 trials	 among	
patient	populations	traditionally	considered	to	be	at‐risk	for	nonad‐













decreased	 adherence	 over	 12‐week	 treatment.36	 Additionally,	 as	
evidenced	by	the	 low	rate	of	virologic	failure	using	a	modified	ITT	
analysis,	 G/P	 provides	 a	 durable	 treatment	 regimen	with	 similarly	
high	efficacy	in	patients	who	are	nonadherent	(<80%)	compared	to	
those	who	are	adherent.37
In	 the	 era	 of	 IFN‐free	 DAAs,	 concerns	 over	 DDIs,	 not	 safety,	
are	 relevant	 to	 treatment	 decisions	 for	 patients	 with	 psychiatric	












CYP3A4	 inhibitor	 could	potentiate	DDIs	with	 the	common	neuro‐
psychiatric	 co‐medications,	 quetiapine,	 hydrocodone	 and	 oxyco‐
done.18	Overall,	G/P	was	safe	and	efficacious	in	patients	taking	any	
of	these	neuropsychiatric	co‐medications	with	potential	DDIs.
Neuropsychiatric	 manifestations	 of	 HCV	 are	 commonly	 re‐
ported,	 and	 their	 severity	 can	be	 alleviated	with	 the	 achievement	
of	SVR.1	In	G/P's	clinical	trials	programme	reported	here,	the	trends	










patient	populations.	 It	 is	 not	 valid	 to	 compare	psychiatric	AEs	be‐
tween	patients	with	or	without	a	psychiatric	disorder	as	 there	are	
most	likely	to	be	different	risk	factors	or	comorbidities	for	each	of	
these	groups	contributing	 to	 their	psychiatric	AEs.	The	 ideal	 anal‐
ysis	would	 involve	a	direct	comparison	of	patients	 treated	with	or	
without	 G/P	 with	 psychiatric	 disorders.	 Additionally,	 the	 patients	
with	 psychiatric	 disorders	 enrolled	 in	 clinical	 trials	 are	 a	more	 se‐
lected	 population	 potentially	 with	 more	 controlled	 disorders	 and	
an	 underrepresentation	 of	 Black	 or	 African‐Americans	 compared	
to	 patients	 in	 the	 real‐world	 setting;	 therefore,	 it	 is	 important	 to	
validate	 these	 findings	with	data	obtained	 from	 real‐world	 clinical	
practice.	Of	note,	30%	of	patients	with	psychiatric	disorders	were	






     |  959BACK et Al.
may	or	may	not	have	included	an	uncontrolled	psychiatric	disorder.	
Full	 details	 are	 listed	 in	 the	 Supporting	 Information.	 Finally,	 treat‐
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